The spread of coronavirus disease (COVID-19) to South Africa in early 2020 has impacted South Africa’s health system and led to public health measures to reduce the spread of the virus. We sought to explore the experiences, challenges and responses of health-care workers based in public healthcare facilities in the Gauteng Province of South Africa provisions as a result of the COVID-19 pandemic or the government response to
Many low- and middle-income countries have adopted performance-based incentives (PBI) programmes to improve outputs, quality and even coverage of their healthcare services through the use of primarily financial incentives to motivate healthcare providers. This study aims to explore opinions and perceptions of financial and non-financial PBI programmes from the perspective of healthcare workers (HCWs) in HIV healthcare services.
HE²RO is pleased to announce that we will be part of the 7th SA TB conference from the 13th - 16 September, 2022 and will be held at the Durban ICC International Convention
Literature regarding the costs and cost-effectiveness of diagnosing breast disease globally, including cancer, has focused on mammographic screening in high-income settings. South Africa, a middle-income country, is currently crafting its first national breast cancer policy, and information on costs and best practices for national imaging services in low- and middle-income settings is required. We undertook this work to estimate the average cost per procedure and per patient for diagnosis of
Women with HIV face an increased risk of human papillomavirus (HPV) acquisition and persistence, cervical intraepithelial neoplasia, and invasive cervical cancer. Our objective was to determine the cost-effectiveness of different cervical cancer screening strategies among women with HIV in South
Drug resistant-tuberculosis is a growing burden on the South African health care budget. In response the National Department of Health implemented two important strategies in 2011; universal access to drug-sensitivity testing for rifampicin with Xpert MTB/RIF as the first-line diagnostic test for TB; and decentralization of treatment for RR/MDR-TB to improve access and reduce costs of
Many low- and middle-income countries face challenges in attaining adequate levels of vaccination coverage, and the factors driving this under-coverage have not been completely elucidated. In this cross-sectional study, we investigated factors associated with vaccination coverage in Mopani District, Limpopo Province, South Africa. Between July and October 2017, we surveyed 317 caregivers (83% of whom were mothers) of seven-month-old infants in Mopani District about barriers faced when attaining
In this so-called treat-all era, antiretroviral therapy (ART) interruptions contribute to an increasing proportion of HIV infections and deaths. Many strategies to improve retention on ART cost more than standard of care. In this study, we aimed to estimate the upper-bound costs at which such interventions should be
HIV treatment programs face challenges in identifying patients at risk for loss-to-follow-up and uncontrolled viremia. We applied predictive machine learning algorithms to anonymised, patientlevel HIV programmatic data from two districts in South Africa, 2016–2018. We developed patient risk scores for two outcomes: (1) visit attendance≤ 28 days of the next scheduled clinic visit and (2) suppression of the next HIV viral load (VL). Demographic, clinical, behavioral and laboratory data were
Abstract Background: Influenza accounts for a substantial number of deaths and hospitalisations annually in South Africa. To address this disease burden, the South African National Department of Health introduced a trivalent inactivated influenza vaccination programme in 2010. Methods: We adapted and populated the WHO Seasonal Influenza Immunization Costing Tool (WHO SIICT) with country-specific data to estimate the cost of the influenza vaccination programme in South Africa. Data were
The 24th International AIDS Conference will commence on the 29th of July and ending on the 2nd of August. We will be presenting on various topics. Access our HE2RO BU Presentation Flyer AIDS 2022 by clicking on the PDF file
TLD: Private-sector market overview(Aug-19 to Jul-20) For further information on TEE(Tenofovir, Emtricitabine, Efavirenz) volumes, estimates of patient numbers and payment-methods for the private-sector (Aug-19 to Jul-20) use the above
